The interim results of the MASTERKEY-265/KEYNOTE-034 phase Ib/III trial (NCT02263508) revealed that the combination therapy resulted in an objective response rate of 62%, with a complete response rate of 33%, no DLT, increased intratumoral expression level of PD-L1, and increased amounts of circulating T cells, inflaming both the virus-injected and non-injected distal tumor sites [23]. The gene discussed is CD274; the disease is neoplasm.